Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01870791
Other study ID # 11122
Secondary ID 2011-003950-24
Status Terminated
Phase Phase 2
First received May 28, 2013
Last updated May 25, 2016
Start date May 2012
Est. completion date December 2015

Study information

Verified date May 2016
Source University Hospitals, Leicester
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

The prognosis for patients with advanced oesophago-gastric cancer is poor. Approximately 16,000 patients in the United Kingdom die from the disease. In spite of new chemotherapy regimens, the average survival for these patients is around 9 months from diagnosis.

Omegaven is an infusion comprising omega-3 fish oils. There is evidence that omega-3 fish oil supplementation can improve general well-being and quality of life in patients receiving palliative chemotherapy for a number of different cancer types. It has also been suggested that omega-3 fish oil supplementation may reduce the toxicity of chemotherapy.

This clinical trial aims to see whether the addition of Omegaven to EOX chemotherapy, the most widely used regimen for patients with advanced oesophago-gastric cancer, will make this drug regimen more effective at killing oesophago-gastric cancer cells, such that disease progression is delayed. Forty-five patients who have been diagnosed with advanced oesophago-gastric cancer will be recruited over a two year period to receive standard chemotherapy and omega-3 fish oil supplementation. The results in these 45 patients will be compared to a matched historical control group of patients who have received identical chemotherapy. If results suggest that the combination of EOX and Omegaven is sufficiently effective, tolerable and feasible then it will be the intention of the trial team to take the combination forward to treat patients with advanced oesophago-gastric cancer in a randomised study.


Recruitment information / eligibility

Status Terminated
Enrollment 21
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed gastric or oesophageal carcinoma (irrespective of subtype), deemed incurable as a result of standard staging investigations.

- Measurable disease according to RECIST v1.1 criteria on CT within 4 weeks of study entry

- World Health Organization Performance status 0-2

- Aged >18 years

- Able to give informed written consent

- Life expectancy >12 weeks

- Adequate hepatic and renal function documented within 7 days prior to treatment (estimated glomerular filtration rate>50ml/min, serum bilirubin < 1.5x upper limit of normal; Alanine transaminase or aspartate transaminase < 2.5x upper limit of normal; Alkaline phosphatase< 3x upper limit of normal (in the absence of liver metastases). If liver metastases are present, serum transaminases < 5x upper limit of normal are permitted.)

- Adequate bone marrow function documented within 7 days (haemoglobin =9g/dL, platelets =100,000cells/mm3, neutrophil count =1500cells/mm3)

- Women of childbearing age must have a negative pregnancy test (urine or serum) at commencement of treatment

- Willing to use contraception if applicable

- Willingness to comply with scheduled visits, treatment, laboratory test, and other aspects of the trial

Exclusion Criteria:

- Prior radical treatment within 6 months of relapse

- Prior treatment with any systemic chemotherapy for metastatic disease

- Prior adjuvant radio- or chemotherapy within 4 weeks of starting the study

- Patients with locally advanced disease deemed suitable for radical chemo-radiotherapy

- Known hyperlipidaemic state

- Hypersensitivity to fish- or egg protein or to any of the active substances or constituents in the lipid emulsion

- Patients with known coagulation disorders

- Any general contra-indications to infusion therapy - pulmonary oedema, hyperhydration, decompensated cardiac insufficiency

- Any unstable medical conditions - uncontrolled diabetes mellitus, acute myocardial infarction, stroke, embolic disease, metabolic acidosis, sepsis, pancreatitis

- Known HIV or hepatitis B or C carrier

- Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with requirements of the protocol

- History of malignancy other than gastric or oesophageal cancer, with the exception of curative treatment for skin cancer (other than melanoma) or in situ breast or cervical carcinoma, or those treated with curative intent for any other cancer with no evidence of disease for 5 years

- Major surgical procedure or significant traumatic injury within 4 weeks of treatment

- Cerebral metastases

- History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan

- Known peripheral neuropathy > Grade 1 (absence of deep tendon reflexes as the sole neurological abnormality does not render the patient ineligible).

- Lack of physical integrity of the upper gastro-intestinal tract, malabsorption syndrome, or inability to take oral medication (administration of capecitabine by naso-gastric or jejunostomy feeding tube is permitted).

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Omegaven
Weekly omegaven infusion in combination with EOX chemotherapy

Locations

Country Name City State
United Kingdom University Hospitals of Leicester NHS Trust Leicester Leicestershire

Sponsors (1)

Lead Sponsor Collaborator
University Hospitals, Leicester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Survival Progression free survival from enrolment to disease progression 12 months No
Secondary Safety profile The number of participants requiring dose delays 12 months Yes
Secondary Efficacy Objective response rate as assessed by RECIST v1.1 6 and 12 months No
Secondary Safety profile The number of participants experiencing adverse effects 12 months Yes
Secondary Safety profile The number of participants requiring dose modifications 12 months Yes
Secondary Safety profile The number of participants requiring treatment withdrawal due to adverse effects 12 months Yes
See also
  Status Clinical Trial Phase
Completed NCT02543411 - Use of Lidocaine in Endoscopic Submucosal Dissection N/A
Completed NCT02128243 - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer Phase 2
Active, not recruiting NCT00506207 - A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy Phase 1
Completed NCT04830618 - Aberrant DNA Methylation to Predict Metachronous Gastric Neoplasms
Completed NCT02235246 - The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Phase 4
Completed NCT00252161 - A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer Phase 3
Recruiting NCT04622098 - Prevalence of Sub-epithelial Lesions Among Patients Undergoing EGDs in Egypt
Completed NCT03255070 - A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) Phase 1
Recruiting NCT06342427 - Stomach Cancer Exosome-based Detection
Recruiting NCT04780256 - Endoscopic Resection of Gastrointestinal Neoplasms
Recruiting NCT03065257 - Endoscopic Resection Multicenter Registry N/A
Recruiting NCT05804331 - The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
Completed NCT05265221 - Learning Curve for Gastric Endoscopic Submucosal Dissection
Recruiting NCT03597581 - A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer Phase 1
Completed NCT00112099 - GCSSG-SPNX: Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: JCOG0110 Phase 3
Recruiting NCT04466631 - Health and Employment After Gastro Intestinal Surgery - HEAGIS2
Completed NCT00149279 - A Trial to Evaluate Para-aortic Lymphadenectomy for Gastric Cancer Phase 3
Terminated NCT00149266 - Randomized Controlled Trial to Evaluate Surgical Approaches to Gastric Cancer Invading the Esophagus (JCOG9502) Phase 3
Recruiting NCT06362070 - Comparison of Outcomes of Multiple Platforms for Assisted Robotic - Gastrectomy N/A
Completed NCT01824953 - Long-term Follow-up Prognosis of Atrophic Gastritis After 3 Years N/A